Project Description:
Title: NFX-179-NF1-202: A randomized, double-blind, vehicle-controlled, parallel group phase 2 dose-response study to determine safety and effectiveness of two concentrations of NFX-179 gel in subjects with cutaneous neurofibromas
Role: Site PI
Funding: Nflexion Therapeutics
2022-present
Summary: This is a randomized, double blind, placebo-controlled study to determine the safety and efficacy of 2 concentrations of NFX-179 gel in subjects with NF1 for treatment of cutaneous neurofibromas.